These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 25309634)
21. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases. Dornan GL; Burke JE Front Immunol; 2018; 9():575. PubMed ID: 29616047 [TBL] [Abstract][Full Text] [Related]
22. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases. Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213 [TBL] [Abstract][Full Text] [Related]
23. Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH Zhang M; Jang H; Gaponenko V; Nussinov R Biophys J; 2017 Nov; 113(9):1956-1967. PubMed ID: 29117520 [TBL] [Abstract][Full Text] [Related]
24. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R). Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696 [TBL] [Abstract][Full Text] [Related]
25. Single-Molecule Study Reveals How Receptor and Ras Synergistically Activate PI3Kα and PIP Buckles TC; Ziemba BP; Masson GR; Williams RL; Falke JJ Biophys J; 2017 Dec; 113(11):2396-2405. PubMed ID: 29211993 [TBL] [Abstract][Full Text] [Related]
26. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460 [TBL] [Abstract][Full Text] [Related]
27. Structural basis of nSH2 regulation and lipid binding in PI3Kα. Miller MS; Schmidt-Kittler O; Bolduc DM; Brower ET; Chaves-Moreira D; Allaire M; Kinzler KW; Jennings IG; Thompson PE; Cole PA; Amzel LM; Vogelstein B; Gabelli SB Oncotarget; 2014 Jul; 5(14):5198-208. PubMed ID: 25105564 [TBL] [Abstract][Full Text] [Related]
28. Structural insights into the activation mechanism of phosphoinositide 3-kinase alpha. Jani V; Sonavane U; Sawant S Comput Biol Chem; 2024 Feb; 108():107994. PubMed ID: 38043374 [TBL] [Abstract][Full Text] [Related]
29. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702 [TBL] [Abstract][Full Text] [Related]
30. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations. Leontiadou H; Galdadas I; Athanasiou C; Cournia Z Sci Rep; 2018 Oct; 8(1):15544. PubMed ID: 30341384 [TBL] [Abstract][Full Text] [Related]
31. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105 [TBL] [Abstract][Full Text] [Related]
32. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755 [TBL] [Abstract][Full Text] [Related]
33. Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation. Liu X; Yang S; Hart JR; Xu Y; Zou X; Zhang H; Zhou Q; Xia T; Zhang Y; Yang D; Wang MW; Vogt PK Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725156 [TBL] [Abstract][Full Text] [Related]
34. Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α. Zhang M; Li Z; Wang G; Jang H; Sacks DB; Zhang J; Gaponenko V; Nussinov R J Phys Chem B; 2018 Dec; 122(49):11137-11146. PubMed ID: 30047727 [TBL] [Abstract][Full Text] [Related]
35. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers. Nussinov R; Zhang M; Tsai CJ; Jang H Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261 [TBL] [Abstract][Full Text] [Related]
36. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Zhao L; Vogt PK Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2652-7. PubMed ID: 18268322 [TBL] [Abstract][Full Text] [Related]
37. Free energy landscape of the PI3Kα C-terminal activation. Kotzampasi DM; Papadourakis M; Burke JE; Cournia Z Comput Struct Biotechnol J; 2024 Dec; 23():3118-3131. PubMed ID: 39229338 [TBL] [Abstract][Full Text] [Related]
38. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP. Menteş M; Karakuzulu BB; Uçar GB; Yandım C Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959 [TBL] [Abstract][Full Text] [Related]
39. Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight. Sharma J; Bhardwaj V; Purohit R ACS Omega; 2019 Oct; 4(14):15815-15823. PubMed ID: 31592171 [TBL] [Abstract][Full Text] [Related]
40. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Zhao L; Vogt PK Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]